ISPOL'ZOVANIE NESTEROIDNYKh PROTIVOVOSPALITEL'NYKh SREDSTV I RISK KARDIOVASKULYaRNYKh OSLOZhNENIY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Nonsteroidal antiinflammatory drugs (NSAIDs) increase the risk of cardiovascular morbidity and cardiovascular mortality, regardless of their selectivity for inhibition of cyclooxygenase-2 (COX-2). The article summarizes the evidence from randomized, controlled and observational studies on cardiovascular safety of NSAIDs. Meloxicam, one of selective COX-2 inhibitors, has lowest risk of myocardial infarction. Among the non-selective NSAIDs, naproxen has the lowest cardiovascular risk. Nevertheless, the use of any NSAID may lead to the development of any possible cardiovascular complications, especially in patients with comorbid cardiovascular diseases. In this regard, recommending the use of the lowest possible doses of NSAIDs and in a shorter time seem to be quite reasonable.

Full Text

Restricted Access

About the authors

N. V Chichasova

References

  1. Насонов Е.Л. Болевой синдром при патологии опорно-двигательного аппарата. Врач 2002; 4: 15-9.
  2. Каратеев А.Е., Алексеева Л.И., Филатова Е.Г. и др. Обезболивающая терапия в терапевтической практике. М., 2013. С. 66-85.
  3. Janssen M., Dijkmans B., van der Sluijs F.A. Upper gastrointestinal complaints and complication in chronic rheumatic patients in comparison with other chronic diseases. Br. J. Rheum. 1992; 31: 747-52.
  4. Solomon S.D., McMuray J.J., Pfeffer M.A., et. al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 2005; 352: 1071-80.
  5. Bombardier C., Laine L., Reiein A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 2000; 343: 1520-28.
  6. Kadam U.T., Jordan K., Craft P.R. Clinical comorbidity in patients with osteoarthritis: a case-control study of general practice consulters in England and Walls. Ann Rheum Dis. 2004; 63: 408-14.
  7. Caporali R., Cimmino M.A., Sazzi-Puttini P., et al. Osteoarthritis in general and specialist practice in Italy: the AMICA study. Sem. Arthr. Rheumat. 2006; 35: 31-7.
  8. Верткин А.Л., Наумов А.В. Остеоартроз: стратегия ведения больных при соматической патологии. РМЖ. 2007; 15(4): 1-6.
  9. Верткин А.Л., Алексеева Л.И., Наумов А.В. и др. Остеоартроз в практике врача-терапевта. РМЖ. 2008; 16(7): 24-9.
  10. Rosemann T., Laux G., Szecsenyi J. Osteoarthritis: quality of life, comorbidities, medication and health service utilization assessed in a large sample of primary care patients. J. Orthoped. Surg. 2007; 2: 12
  11. van Dijk G.M., Venhof C., Schellevis F., et al. Comorbidity, limitation in activities and pain in patients with osteoarthritis of the hip or knee. BMS Musculoskeletal Disord. 2008; 9: 95-9.
  12. Antman E.M., DeMets D., Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation. 2005; 112: 759-70.
  13. Grosser T., Fries S., FitzGerald G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 2006; 116: 4-15.
  14. Topper J.N., Cai J., Falb D., Gimbrone M.A. Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc. Natl. Acad. Sci. USA 1996; 93: 10417-22.
  15. Rainsford K.D. Anti-inflammatory drugs in the 21st century. Subcell Biochem. 2007; 42: 3-27.
  16. Rao P., Knaus E.E. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase inhibition and beyond. J. Pharm. Parm. Sci. 2008; 11: 81S-110S.
  17. Timmers L., Sluijter J.P., Verlaan C.W., et al. Cyclooxigenase-2 inhibition increase mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig. Circulation.2007; 116: 326-32.
  18. Francois H., Athirakul K., Howell D., et al. Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab. 2005; 2: 201-07.
  19. Hippisley-Cox J., Coupland C. Risk of myocardial infarction in patients taking cyclo-oxigenase-2 inhibitors or conventional non-steroidal antiinflammatory drugs: population based nested case-control analysis. BMJ. 2005; 330: 1366.
  20. Johnsen S.P., Larsson H., Tarone R.E., et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, an over NSAIDs: a population-based case-control study. Arch. Int. Med. 2005; 165: 978-84.
  21. Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet. 2007; 370: 2138-51.
  22. Dai C., Stafford R.S., Alexander G.C. National trends in cyclo-oxigenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Arch. Intern. Med. 2005; 165: 171-77.
  23. Garcia Rodriguez L.A., Tacconelli S., Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J. Am. Coll. Cardiol. 2008; 52: 1628-36.
  24. Levesque L.E., Brophy J.M., Zhang B. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. CMAJ. 2006; 174: 1563-69.
  25. Antman E.M., Bennett J.S., Daugherty A., et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007; 115: 1634-42.
  26. Minuz P. Nonsteroidal anti-inflammatory drugs and cardiovascular risk: is prostacyclin inhibition the key event? J. Am. Coll. Cardiol. 2008; 52: 1637-39.
  27. Solomon S.D., Vittes J., Finn P.V., et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008; 117: 2104-13.
  28. Cardiovascular and cerebrovascular events in randomized, controlled Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). PLoS Clin. Trials. 2006; 1: 33.
  29. Ladacos S.W. Time-to-event analysis for longterm treatments - the APPROVe trial. N. Engl. J. Med. 2006; 355: 113-17.
  30. Layton D., Heely E., Hughes K., Shakir S. Comparison of the incidence of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheum. 2003; 42: 1342-53.
  31. Layton D., Hughes K., Harris S., Shakir S. Comparison of the incidence of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatol. 2003; 42: 1 354-64.
  32. Cannon C.P., Curris S.P., FitzGerald G.A., et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomized comparison. Lancet. 2006; 368: 1771-81.
  33. Singh G. Meloxicam does not increase the risk of acute myocardial infarction, congestive heart failure, edema or hypertension compared to NSAIDs: results from a pooled analysis of 27039 patients [abstract]. Eur. Congress Rheumatology. Prague, 2001, June 13-6.
  34. Van Ryn J., Kink-Einbad M., Kuritsch I., et al. Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. Clin. Pharm. 2004; 44: 777-84.
  35. Singh G. Comparison of risk of acute myocardial infarction of selective and non-selective antiinflammatory drugs. Ann. Rheum. Dis. 2006; 65(Suppl II): 61.
  36. Altman A., Luciardi H., Muntaner J., et al. Efficacy assessment of meloxicam, a preferential cyclooxigenese-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the non-steroidal anti-inflammatory drugs in instable angina treatment-2 (NUT-2) pilot study. Circulation. 2002; 106: 191-95.
  37. Lewis M.F., Miller D.R., Rahme E., et, al. Comparison of the evidence myocardial infarction in patients treated selective and non-selective inhibitors COX-2. Pharmacoepidemiol. Drug Saf. 2006; 15: S59.
  38. Fosbol E.L., Gislason G.H., Jacobsen S., et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin. Pharmacol. Ther. 2009; 85: 190-97.
  39. Gislason G.H., Jcobsen S., Rasmussen J.N., et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction, Circulation. 2006; 113: 2906-13.
  40. Graham D.J., Campen D., Hui R., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxigenase selective and non-selective non-steroidal antiinflammatory drugs: nested case-control study. Lancet. 2005; 365: 475-81.
  41. Brophy J.M., Levesque L.E., Zhang B. The coronary risk of cyclo-oxigenase-2 inhibitors in patients with a previous myocardial infarction. Heart. 2007; 93: 189-94.
  42. Kearney P.M., Baigent C., Godwin J., et al. Do selective cyclo-oxigenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherotrombosis? Meta-analysis of randomised trials. BMJ. 2006; 332; 1302-08.
  43. Tai-Juan A., Haas S.J., Liew D., Kran H. Metaanalysis of cyclooxygenase-2 inhibitors and their effect on blood pressure. Arch Int. Med. 2005; 165: 490-96.
  44. Scott P.A., Kingsley G.H., Scott D. Nonsteroidal anti-inflammatory drugs and cardiac failure meta-analysis of observations studies and randomised trials. Eur. J. Heart Failure. 2007; 10: 1102-07.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media